Shiva Ostadrahimi

Dr. Shiva Ostadrahimi

UT Health San Antonio

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2018 in Biotechnology and Applied Biochemistry
Verified
Journal Article
Closed access
PDF file
MPMonireh ParvizHamidi
Monireh ParvizHamidi
GHGhazal Haddad
Ghazal Haddad
Shiva OstadrahimiShiva Ostadrahimi
Shiva Ostadrahimi
NONima Ostadrahimi
Nima Ostadrahimi
SSSedigheh Sadeghi
Sedigheh Sadeghi
PFPezhman Fard-Esfahani
Pezhman Fard-Esfahani

1 August 2018
Verified
Journal Article
Open access
PDF file
Shiva OstadrahimiShiva Ostadrahimi
Shiva Ostadrahimi
MAManuchehr Abedi-Valugerdi
Manuchehr Abedi-Valugerdi
Moustapha HassanMoustapha Hassan
Moustapha Hassan
GHGhazal Haddad
Ghazal Haddad
SFShima Fayaz
Shima Fayaz
PFPezhman Fard-Esfahani
Pezhman Fard-Esfahani
Objective: Small non-coding RNA molecules are dysregulated in prostate cancer (PCa). In our previous study,downregulation of miR-1266 and miR-185 was demonstrated in PCa tissues and cell lines. The aim of the presentstudy was to investigate whether miR-1266 and miR-185 are involved in the regulation of B-cell lymphoma (BCL) 2and BCL2L1, respectively, and whether transfection of PCa cell lines with miR-1266 and miR-185 mimics can altertumorigenic phenotypes. Methods: In order to investigate the regulation of BCL2 and BCL2L1 mRNA levels bymiR-1266 and miR-185, respectively, a luciferase reporter assay was used. Real-time PCR was also used to analyzechanges in the levels of BCL2 and BCL2L1 mRNAs in PCa cell lines following transfection with synthetic miR-1266and miR-185. Cell apoptosis was determined by Annexin V protein expression analysis via flow cytometry. In additionto the MTT assay, a cell proliferation assay was performed. Result: A luciferase assay confirmed that the BCL2 andBCL2L1 genes may be targeted by miR-1266 and miR-185, respectively, through binding to their 3′UTR regions.Transfection of PC3 and DU145 cells with miR-1266 and miR-185 induced apoptosis and reduced proliferation, whichalso revealed an inverse correlation with BCL2 and BCL2L1 gene expression in the treated cells. Conclusion: Ourdata suggests that miR-1266 and miR-185 may be novel candidates for further research in PCa treatment through theanti-apoptotic pathway.

23 March 2018 in Oncology Letters
Verified
Journal Article
Closed access
PDF file
Shiva OstadrahimiShiva Ostadrahimi
Shiva Ostadrahimi
SFShima Fayaz
Shima Fayaz
MPMonireh Parvizhamidi
Monireh Parvizhamidi
MAManuchehr Abedi-Valugerdi
Manuchehr Abedi-Valugerdi
Moustapha HassanMoustapha Hassan
Moustapha Hassan
PFPezhman Fard-Esfahani
Pezhman Fard-Esfahani
Over the latest decade, the role of microRNAs (miRNAs/miRs) has received more attention. miRNAs are small non‑coding RNAs that may serve a role as oncogenes or tumor suppressor genes. Certain miRNAs regulate the apoptosis pathway by influencing pro‑ or anti‑apoptotic genes. We hypothesized that increases in the expression of B cell lymphoma 2 (BCL2) and BCL2‑like 1 (BCL2L1) genes, which have been reported in various types of cancer tissues, may be due to the downregulation of certain miRNAs. The present study aimed to identify miRNAs that target BCL2 and BCL2L1 anti‑apoptotic genes in prostate cancer (PCa) clinical tissue samples. Certain candidate miRNAs were selected bioinformatically and their expression in PCa samples was analyzed and compared with that in benign prostatic hyperplasia (BPH) tissue samples. The candidate miRNAs that targeted BCL2 and BCL2L1 genes were searched in online databases (miRWalk, microRNA.org, miRDB and TargetScan). A total of 12 miRNAs that target the 3'‑untranslated region of the aforementioned genes and/or for which downregulation of their expression has previously been reported in cancer tissues. A total of 30 tumor tissue samples from patients with PCa and 30 samples tissues from patients with BPH were obtained and were subjected to reverse transcription‑quantitative polymerase chain reaction for expression analysis of 12 candidate miRNAs, and the BCL2 and BCL2L1 genes. Additionally, expression of 3 finally selected miRNAs and genes was evaluated in prostate cancer PC3 and DU145 cell lines and human umbilical vein endothelial cells. Among 12 miRNA candidates, the expression of miR‑1266, miR‑185 and miR‑30c‑2 was markedly downregulated in PCa tumor tissues and cell lines. Furthermore, downregulation of these miRNAs was associated with upregulation of the BCL2 and BCL2L1 genes. An inverse association between three miRNAs (miR‑1266, miR‑185 and miR‑30c‑2) and two anti‑apoptotic genes (BCL2 and BCL2L1) may be considered for interventional miRNA therapy of PCa.

14 January 2021 in Cancers
Verified
Journal Article
Open access
PDF file
AKAdam Kosti
Adam Kosti
RBRodrigo Barreiro
Rodrigo Barreiro
GGGabriela Der Agopian Guardia
Gabriela Der Agopian Guardia
Shiva OstadrahimiShiva Ostadrahimi
Shiva Ostadrahimi
EKErzsebet Kokovay
Erzsebet Kokovay
Luiz PenalvaLuiz Penalva
Luiz Penalva
Tumor suppressor microRNAs (miRNAs) have been explored as agents to target cancer stem cells. Most strategies use a single miRNA mimic and present many disadvantages, such as the amount of reagent required and the diluted effect on target genes. miRNAs work in a cooperative fashion to regulate distinct biological processes and pathways. Therefore, we propose that miRNA combinations could provide more efficient ways to target cancer stem cells. We have previously shown that miR-124, miR-128, and miR-137 function synergistically to regulate neurogenesis. We used a combination of these three miRNAs to treat glioma stem cells and showed that this treatment was much more effective than single miRNAs in disrupting cell proliferation and survival and promoting differentiation and response to radiation. Transcriptomic analyses indicated that transcription regulation, angiogenesis, metabolism, and neuronal differentiation are among the main biological processes affected by transfection of this miRNA combination. In conclusion, we demonstrated the value of using combinations of neurogenic miRNAs to disrupt cancer phenotypes and glioma stem cell growth. The synergistic effect of these three miRNA amplified the repression of oncogenic factors and the effect on cancer relevant pathways. Future therapeutic approaches would benefit from utilizing miRNA combinations, especially when targeting cancer-initiating cell populations.

30 April 2008 in Gastroenterology
Verified
Journal Article
Closed access
SNSiavosh Nasseri-Moghaddam
Siavosh Nasseri-Moghaddam
HRHadi Razjouyan
Hadi Razjouyan
MMMansoureh Mamarabadi
Mansoureh Mamarabadi
SASeyed-Maysam Alimohamadi
Seyed-Maysam Alimohamadi
AMAzadeh Mofid
Azadeh Mofid
RMReza Malekzadeh
Reza Malekzadeh

31 May 2009 in Gastroenterology
Verified
Journal Article
Closed access
HRHadi Razjouyan
Hadi Razjouyan
SNSiavosh Nasseri-Moghaddam
Siavosh Nasseri-Moghaddam
BABehnoush Abedi Ardekani
Behnoush Abedi Ardekani
MSMasoud Sotoudeh
Masoud Sotoudeh
MMMansoureh Mamarabadi
Mansoureh Mamarabadi
RMReza Malekzadeh
Reza Malekzadeh